.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,635,234

« Back to Dashboard
Patent 6,635,234 protects XOFIGO and is included in one NDA.

This patent has thirty-one patent family members in twenty-one countries.

Summary for Patent: 6,635,234

Title: Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
Abstract:Processes for the preparation, prepared solutions, and the use of radium-223 for the treatment of calcified tumors, bone tumors, treatment of bones, bone surfaces and soft tissues is described.
Inventor(s): Larsen; Roy H. (Bekkestua, NO), Henriksen; Gjermund (Mj.o slashed.ndalen, NO), Bruland; .O slashed.yvind S. (Hosle, NO)
Assignee: Anticancer Therapeutic Inventions AS (Oslo, NO)
Application Number:09/476,569
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 8th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
XOFIGO
radium ra-223 dichloride
SOLUTION;INTRAVENOUS203971-001May 15, 2013RXYes6,635,234► subscribe THERAPEUTIC TREATMENT OF BONE METASTASES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,635,234

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Norway19990001Jan 04, 1999

International Patent Family for Patent: 6,635,234

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria331534► subscribe
Australia1700400► subscribe
Australia774991► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc